Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
ORGANIZATION
JPMA Reshaping Organization to Boost Agility as It Shifts to Legal Entity
The Japan Pharmaceutical Manufacturers Association (JPMA) is moving to overhaul its organizational structure as it seeks to acquire a legal corporate status, aiming to strengthen its ability to respond more quickly to increasingly complex domestic and global challenges. The JPMA…
To read the full story
Related Article
- JPMA Launches New Legal Entity, Set for October Transition
May 1, 2026
- JPMA to Set Up Task Force on US MFN Policy, First Meeting Seen This Month
April 21, 2026
- JPMA to Prepare Response to US “MFN” Policy under New Strategy Unit
April 2, 2026
- JPMA Unveils Committee Action Plans, Prioritizes Innovation-Focused Drug Pricing
April 2, 2026
ORGANIZATION
- Ectopic Fat Research Group Launches to Push Cross-Disciplinary Studies
July 31, 2026
- JPMA Chief Seeks Concrete Reforms to Reward Innovation after Honebuto
July 31, 2026
- Patient Groups Launch Consortium to Improve Access to Drug Information
July 31, 2026
- Radiopharma Group Seeks Faster NHI Coverage for PET Imaging Agents
July 28, 2026
- Generic, Biosimilar Society Adopts 2040 Vision for Japan’s Pharma Industry
July 27, 2026
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…